Literature DB >> 16987733

Treatment of dystonia.

Joseph Jankovic1.   

Abstract

Dystonia, defined as a neurological syndrome characterised by involuntary, patterned, sustained, or repetitive muscle contractions of opposing muscles, causing twisting movements and abnormal postures, is one of the most disabling movement disorders. Although gene mutations and other causes are increasingly recognised, most patients have primary dystonia without a specific cause. Although pathogenesis-targeted treatment is still elusive, the currently available symptomatic treatment strategies are quite effective for some types of dystonia in relieving involuntary movements, correcting abnormal posture, preventing contractures, reducing pain, and improving function and quality of life. A small portion of patients have a known cause and respond to specific treatments, such as levodopa in dopa-responsive dystonia or drugs that prevent copper accumulation in Wilson's disease. Therapeutic options must be tailored to the needs of individual patients and include chemodenervation with botulinum toxin injections for patients with focal or segmental dystonia, and medical treatments or deep brain stimulation for patients with generalised dystonia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16987733     DOI: 10.1016/S1474-4422(06)70574-9

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  61 in total

Review 1.  Use of botulinum toxin in the neurology clinic.

Authors:  Erle C H Lim; Raymond C S Seet
Journal:  Nat Rev Neurol       Date:  2010-10-12       Impact factor: 42.937

Review 2.  Current and emerging strategies for treatment of childhood dystonia.

Authors:  Matteo Bertucco; Terence D Sanger
Journal:  J Hand Ther       Date:  2014-11-15       Impact factor: 1.950

3.  Decreased number of striatal cholinergic interneurons and motor deficits in dopamine receptor 2-expressing-cell-specific Dyt1 conditional knockout mice.

Authors:  Fumiaki Yokoi; Janneth Oleas; Hong Xing; Yuning Liu; Kelly M Dexter; Carly Misztal; Melinda Gerard; Iakov Efimenko; Patrick Lynch; Matthew Villanueva; Raul Alsina; Shiv Krishnaswamy; David E Vaillancourt; Yuqing Li
Journal:  Neurobiol Dis       Date:  2019-10-13       Impact factor: 5.996

Review 4.  Dystonia and leveraging oral pharmacotherapy.

Authors:  Michelle Ann C Sy; Hubert H Fernandez
Journal:  J Neural Transm (Vienna)       Date:  2021-04-20       Impact factor: 3.575

Review 5.  Diagnosis and treatment of dystonia.

Authors:  H A Jinnah; Stewart A Factor
Journal:  Neurol Clin       Date:  2015-02       Impact factor: 3.806

6.  Electromyographic evidence in support of a knock-in mouse model of DYT1 Dystonia.

Authors:  Mark P DeAndrade; Amy Trongnetrpunya; Fumiaki Yokoi; Chad C Cheetham; Ning Peng; J Michael Wyss; Mingzhou Ding; Yuqing Li
Journal:  Mov Disord       Date:  2016-05-31       Impact factor: 10.338

Review 7.  X-Linked Dystonia-Parkinsonism: recent advances.

Authors:  D Cristopher Bragg; Nutan Sharma; Laurie J Ozelius
Journal:  Curr Opin Neurol       Date:  2019-08       Impact factor: 5.710

Review 8.  Treatment strategies for dystonia.

Authors:  Leslie J Cloud; H A Jinnah
Journal:  Expert Opin Pharmacother       Date:  2010-01       Impact factor: 3.889

Review 9.  Task-specific dystonias: a review.

Authors:  Diego Torres-Russotto; Joel S Perlmutter
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

10.  Increased c-fos expression in the central nucleus of the amygdala and enhancement of cued fear memory in Dyt1 DeltaGAG knock-in mice.

Authors:  Fumiaki Yokoi; Mai T Dang; Courtney A Miller; Andrea G Marshall; Susan L Campbell; J David Sweatt; Yuqing Li
Journal:  Neurosci Res       Date:  2009-07-18       Impact factor: 3.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.